179 related articles for article (PubMed ID: 27760587)
1. Truncated Bid Overexpression Induced by Recombinant Adenovirus Cre/LoxP System Suppresses the Tumorigenic Potential of CD133
Long Q; Zhu W; Zhou J; Wu J; Lu W; Zheng C; Zhou D; Yu L; Yang R
Oncol Res; 2017 Apr; 25(4):595-603. PubMed ID: 27760587
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.
Long Q; Yang R; Lu W; Zhu W; Zhou J; Zheng C; Zhou D; Yu L; Wu J
Oncol Rep; 2017 Jan; 37(1):155-162. PubMed ID: 27878291
[TBL] [Abstract][Full Text] [Related]
3. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
4. Truncated Bid Regulates Cisplatin Response via Activation of Mitochondrial Apoptosis Pathway in Ovarian Cancer.
Dai Y; Zhao XJ; Li F; Yuan Y; Yan DM; Cao H; Huang XY; Hu Z; Ma D; Gao QL
Hum Gene Ther; 2020 Mar; 31(5-6):325-338. PubMed ID: 32024383
[TBL] [Abstract][Full Text] [Related]
5. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
6. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133+ Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways.
Shen C; Chen F; Wang H; Li G; Yu C; Wang X; Wen Z
Cell Physiol Biochem; 2018; 49(1):282-294. PubMed ID: 30138944
[TBL] [Abstract][Full Text] [Related]
7. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma.
Miao J; Chen GG; Chun SY; Yun JP; Chak EC; Ho RL; Lai PB
Int J Cancer; 2006 Oct; 119(8):1985-93. PubMed ID: 16708390
[TBL] [Abstract][Full Text] [Related]
10. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.
Xiang T; Long H; He L; Han X; Lin K; Liang Z; Zhuo W; Xie R; Zhu B
Oncogene; 2015 Jan; 34(2):165-76. PubMed ID: 24362529
[TBL] [Abstract][Full Text] [Related]
12. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
[TBL] [Abstract][Full Text] [Related]
13. Tumorigenic lung tumorospheres exhibit stem-like features with significantly increased expression of CD133 and ABCG2.
Zhao W; Luo Y; Li B; Zhang T
Mol Med Rep; 2016 Sep; 14(3):2598-606. PubMed ID: 27432082
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
15. IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway.
Lee YS; Kim KC; Mongre RK; Kim JY; Kim YR; Choi DY; Song S; Yun J; Han SB; Yoon DY; Hong JT
Cell Death Dis; 2019 Jul; 10(7):506. PubMed ID: 31263095
[TBL] [Abstract][Full Text] [Related]
16. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
17. CD133
Liu K; Hao M; Ouyang Y; Zheng J; Chen D
Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312
[TBL] [Abstract][Full Text] [Related]
18. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.
Guo R; Wu Q; Liu F; Wang Y
Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.
Ma L; Lai D; Liu T; Cheng W; Guo L
Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681
[TBL] [Abstract][Full Text] [Related]
20. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells.
Wei X; He J; Wang J; Yang X; Ma B
Tumour Biol; 2015 Nov; 36(11):8931-42. PubMed ID: 26081615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
